07:52 AM EDT, 09/17/2025 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Wednesday that it has acquired worldwide licensing rights for TNX-4800, a monoclonal antibody aimed at Lyme disease prevention, from UMass Chan Medical School, Massachusetts.

Financial details of the agreement were not disclosed.

TNX-4800 is being developed for annual seasonal use, with one subcutaneous dose administered in the spring season to protect against Lyme disease through fall, or the entire tick season in the US, the company said.

Tonix said it plans to advance TNX-4800 through additional clinical trials aimed at eventually submitting a Biologics Licensing Application.

The company said that an early-stage study of TNX-4800 has demonstrated safety, tolerability, and a linear relationship between pharmacokinetics, pharmacodynamics, and efficacy, adding that it is planning an adaptive phase 2/3 study.

Tonix shares were up more than 1% in recent Wednesday premarket activity.